Faron, etusivu

releases and publications

Final Results for the year ended December 31, 2019

Regulatory

FDA accepts protocol for new Traumakine trial

Regulatory

MATINS update

Regulatory

Faron to acquire AOC3 antagonist platform

Regulatory

Traumakine update

Regulatory

Ovarian cancer selected as 2nd MATINS trial cohort

Regulatory

DMC approves colorectal cancer cohort expansion

Regulatory

Update on Traumakine drug substance manufacturing

Regulatory

Matins Trial Update

Regulatory

LIQUIDITY PROVIDING AGREEMENT

Regulatory
PreviousNext
Back to top